Leave a comment

via: news92fm.com

Patients who have been diagnosed with HER2-positive breast cancer may be eligible for a clinical study led by Baylor College of Medicine. The multi-institutional research will evaluate a new method of treatment that combines HER2-targeted therapies and excludes chemotherapy.

The study is a follow-up to a recent clinical trial that showed HER2-positive breast cancer patients using trastuzumab (Herceptin) and lapatinib (Tykerb) for 12 weeks – without chemotherapy. Patients reportedly showed a significant benefit in the eradication of breast cancer tumors. The data was released in May 2011 by the

Read More

Follow

Get every new post delivered to your Inbox.

Join 1,198 other followers